Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most oncology/mechanism statements are not evaluated because they are not present in the supplied embryo-fetal toxicity label excerpts; embryo-fetal risk, pregnancy testing, and contraception/condom counseling are supported. Major coverage gaps exist relative to the provided label-limited scope (no dosing/administration and indication details beyond general oncology context).
Category Scores
Accurate Statements
Vismodegib is used for advanced basal cell carcinoma.
The provided label excerpt includes an indication describing metastatic BCC and locally advanced BCC that has recurred following surgery or is not a candidate for surgery and not a candidate for radiation (Section 1 context).
Vismodegib is used for locally advanced BCC that is not curable with surgery or radiation.
Section 1 indication: locally advanced BCC that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation.
Vismodegib is used for metastatic BCC.
Section 1 indication: treatment of adults with metastatic basal cell carcinoma.
Unsupported Statements
Vismodegib treats basal cell carcinoma (BCC) by blocking the Hedgehog signaling pathway.
Not supported or contradicted by the provided embryo-fetal toxicity label excerpts (5.1, 8.1) and the limited indication/dosage lines; no mechanism statement is included in the supplied text.
Vismodegib inhibits Smoothened (SMO).
Not supported by the provided excerpts.
The Hedgehog signaling pathway helps drive growth of cancer cells in many BCC tumors.
Not supported by the provided excerpts.
By shutting down the Hedgehog signaling pathway, vismodegib can slow or stop tumor growth.
Not supported by the provided excerpts.
Vismodegib can shrink lesions in patients with advanced BCC.
Not supported by the provided excerpts.
Vismodegib is used for advanced basal cell carcinoma.
Only the specific label language (metastatic BCC; locally advanced BCC meeting surgical/radiation candidacy criteria) is provided in the prompt; 'advanced basal cell carcinoma' as a general phrase is not directly stated in the supplied label text.
Contradictions
Important Omissions
Embryo-fetal toxicity counseling elements from the provided label excerpts: verify pregnancy status within 7 days prior to initiating ERIVEDGE; advise pregnant women of potential risk; advise females of reproductive potential to use effective contraception during therapy and for 24 months after final dose; advise males to use condoms during therapy and for 3 months after final dose; advise males not to donate semen during therapy and for 3 months after final dose.
Importance:
Moderate
Specific supported dosing instruction from the provided label excerpts: recommended dosage is 150 mg taken orally once daily.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response does not include the pregnancy testing and contraception/condom/semen-donation precautions required by the provided embryo-fetal toxicity sections, which are material to safe use for reproductive potential patients.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Mechanism/benefit statements (Hedgehog/SMO; lesion shrinkage; tumor growth slowdown) are not supported by the supplied label excerpts, and the key embryo-fetal toxicity counseling content from sections 5.1/8.1 is omitted.
Suggested Improvement
Limit claims to the supplied label excerpts: include embryo-fetal death/severe birth defects risk, pregnancy testing timing, and required contraception/condom and semen donation precautions; avoid or qualify mechanism/efficacy statements not present in the provided label text.